Postprandial Inflammation and Fatty Acids (PIFA)

This study has been completed.
Sponsor:
Collaborator:
Dutch Diabetes Research Foundation
Information provided by:
Wageningen University
ClinicalTrials.gov Identifier:
NCT00977262
First received: September 11, 2009
Last updated: April 20, 2010
Last verified: April 2010

September 11, 2009
April 20, 2010
October 2009
December 2009   (final data collection date for primary outcome measure)
PBMC gene expression profiles [ Time Frame: 0, 2, 4 hrs ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00977262 on ClinicalTrials.gov Archive Site
  • PBMC inflammatory response capacity [ Time Frame: 0, 2, 4 hrs ] [ Designated as safety issue: No ]
  • Endothelial function [ Time Frame: 0, 2, 4 hrs ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Postprandial Inflammation and Fatty Acids
Effects of Fatty Acids on Postprandial Inflammatory Response of Healthy Obese and Type 2 Diabetic Obese Subjects

The main objective is to elucidate the acute effects of an oral intake of either saturated, monounsaturated or polyunsaturated fatty acids on peripheral blood mononuclear cells (PBMC) whole genome expression of obese and type 2 diabetic obese subjects.

Consumption of high-fat diets can lead to postprandial dyslipidemia, impairment of endothelial function, activation of immune cells and changes in gene expression profiles of immune cells such as peripheral blood mononuclear cells (PBMC). Recently it was shown that postprandial gene expression profiles of PBMC and plasma triglyceride (TG) and free fatty acid (FFA) responses are dependent on the type of dietary fat consumed (i.e. saturated, monounsaturated and polyunsaturated). Since obese and diabetic subjects usually are in a pro-inflammatory state and have dyslipidemia and endothelial dysfunction we are interested in the effect of different fatty acids in a high load on the PBMC gene expression profiles, plasma cytokine profiles and endothelial function of these subjects.

Interventional
Not Provided
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
  • Cardiovascular Disease
  • Diabetes Type 2
  • Obesity
  • Other: High saturated fat shake
    milkshake containing 95 gram of fat, high percentage of saturated fat
  • Other: High monounsaturated fat shake
    milkshake containing 95 gram of fat, high percentage of monounsaturated fat
  • Other: High polyunsaturated fat shake
    milkshake containing 95 gram of fat, high percentage polyunsaturated fat
  • Experimental: Healthy control subjects, High saturated fat shake
    Intervention: Other: High saturated fat shake
  • Experimental: Healthy control subjects, High Monounsaturated fat shake
    Intervention: Other: High monounsaturated fat shake
  • Experimental: Healthy control subjects, High Polyunsaturated fat shake
    Intervention: Other: High polyunsaturated fat shake
  • Experimental: Healthy obese subjecs, High saturated fat shake
    Intervention: Other: High saturated fat shake
  • Experimental: Healthy obese subjects, High monounsaturated fat shake
    Intervention: Other: High monounsaturated fat shake
  • Experimental: Healthy obese subjects, High polyunsaturated fat shake
    Intervention: Other: High polyunsaturated fat shake
  • Experimental: Obese diabetes type 2 subjects, High Saturated fat shake
    Intervention: Other: High saturated fat shake
  • Experimental: Obese diabetes type 2 subjects, High Monounsaturated fat shake
    Intervention: Other: High monounsaturated fat shake
  • Experimental: Obese diabetes type 2 subjects, High polyunsaturated fat shake
    Intervention: Other: High polyunsaturated fat shake

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
42
December 2009
December 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

For all participants:

  • male gender
  • 50-70 yrs

For diabetic patients only:

  • BMI >30 kg/m2
  • Well-controlled diabetes: fasting plasma glucose concentration must be <10.0 mmol/l at the time of screening.
  • Must be on sulphonylurea- or metformin therapy for at least 6 months with a constant dose for at least two months, or on dietary treatment for at least 6 months2.

For obese controls only:

  • BMI > 30 kg/m2
  • normoglycemic according to WHO criteria (OGTT, fasting blood glucose< 7 mmol/L, after 2 hr <7.8mmol/L)

For lean controls only:

  • BMI 18-25 kg/m2
  • normoglycemic according to WHO criteria (OGTT, fasting blood glucose< 7 mmol/L, after 2 hr <7.8mmol/L)

Exclusion Criteria:

For all participants:

  • Female gender
  • Age below 50 or above 70 years
  • Hemoglobin levels <8.4 mmol/L
  • Allergic to cow milk or dairy products
  • Allergic to fish oil
  • Vegetarian
  • Tobacco smoker
  • Current or recent (<4 weeks) use of fish oil supplements or more then four times fish/week; 24.35 g of EPA-DHA of fish per month (800 mg/day) as judged by the questionnaire.
  • Received inoculations within 2 months of starting the study or planned to during the study
  • Donated or intended to donate blood from 2 months before the study till two months after the study
  • Unstable body weight (weight gain or loss > 3 kg in the past three months)
  • Medical condition that can interfere with the study outcome (i.e. cardiovascular disease, gastrointestinal disease, renal dysfunction)
  • Use of medications know to interfere with glucose homeostasis (i.e. corticosteroids)
  • abuse of drugs and/or alcohol
  • participation in another biomedical study within 1 month before the first screening visit

For obese, type 2 diabetic subjects only:

  • severe diabetes which requires application of insulin
  • diabetes-related complications

For obese subjects and lean controls only:

  • hyperglycemic according to WHO criteria (OGTT, fasting blood glucose >6.0mM, after 2 hr>11mM)
  • systolic blood pressure >160 mmHg or diastolic blood pressure > 100 mmHg
  • Urinary glucose concentrations (>0.25 g/l)
Male
50 Years to 70 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Netherlands
 
NCT00977262
NL2800108109
No
Wageningen University, Division of Human Nutrition, Wageningen University
Wageningen University
Dutch Diabetes Research Foundation
Study Chair: Michael Muller, Prof Chair Department of Human Nutrition NMG group
Principal Investigator: Lydia A Afman, PhD Senior scientist department Human Nutrition Wageningen University
Wageningen University
April 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP